Startups
Edit
Biosion, In Global For Global, antibody
http://www.biosion.com/Last activity: 03.02.2026
Active
Biosion is a professional leader China Biosion, In Global For Global, antibody-drug conjugate manufacturer with high quality and reasonable price. Welcome to contact us.
Mentions in press and media 17
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 3, 2026 | Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors | Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In Global, For Global" collaboration strategy. NEWARK, Del. and NANJING, Chin... |
| Feb 19, 2025 | Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US | NEWARK, Del. and NANJING, China, Feb. 19, 2025 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical-stage biotechnology company, is pleased to announce the appointment of Kedan Lin, Ph.D., as Chief Development Officer and ... |
| Nov 18, 2024 | Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets | Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales mi... |
| Jun 11, 2024 | Biosion Today Presented Key Phase 2 POC Clinical Study Results for Bosakitug, an Anti-TSLP mAb, in Atopic Dermatitis Subjects at the Revolutionizing Atopic Dermatitis Conference | NEWARK, Del. and NANJING, China, June 11, 2024 /PRNewswire/ -- Biosion, a global, clinical-stage biotechnology company, today presented key results from the ADAMANT study, a phase 2 proof-of-concept trial in AD subjects treated with Bosakit... |
| Mar 21, 2024 | Biosion to Present Three Posters at the 2024 AACR Meeting | NEWARK, Del. and NANJING, China, March 21, 2024 /PRNewswire/ -- Biosion, a global, clinical-stage biotechnology company, today announced upcoming presentations of pre-clinical data for its oncology pipeline assets, including BSI-111, an ant... |
| Jan 8, 2024 | Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC) | - First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024 NEWARK, Del. and N... |
| Jul 5, 2023 | Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development | NEWARK, Del. and NANJING, China, July 5, 2023 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global, clinical-stage biotechnology company, today announced the appointment of Furqan Ahmed, PharmD., as the Vice President and Head of B... |
| May 8, 2023 | Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody | NEWARK, Del. and NANJING, China, May 8, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology company, today announced the upcoming presentation of discovery and development data for BSI-038, an anti-CD40 agonisti... |
| Apr 4, 2023 | Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis | NEWARK, Del. and NANJING, China, April 4, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced that it has successfully opened an IND following review by the U.S. Food and ... |
Show more
Reviews 0
FAQ about Biosion, In Global For Global, antibody
What has the press written about Biosion, In Global For Global, antibody?
Parsers VC has collected 17 articles mentioning Biosion, In Global For Global, antibody, among them “Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid...” (Feb 3, 2026) and “Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US” (Feb 19, 2025).
Is Biosion, In Global For Global, antibody still active?
Yes, Biosion, In Global For Global, antibody is active; its latest activity on Parsers VC dates from Feb 3, 2026.